{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:50:16Z","timestamp":1789840216688,"version":"4.0.1"},"reference-count":258,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Bile acids (BAs) are amphiphilic molecules traditionally recognized for their role in lipid digestion but have gained increased interest for their therapeutic potential. Among them, ursodeoxycholic acid (UDCA) is the most widely prescribed and has been FDA-approved in the treatment of primary biliary cholangitis (PBC), the most common chronic cholestatic liver disease, while also being used off-label in multiple other disorders. The therapeutic effects of BAs are linked to their capacity to modulate signaling pathways, reduce hepatocellular injury, and regulate inflammation. Their physicochemical properties, particularly hydrophobicity, influence both efficacy and toxicity, of which the mechanisms involving receptors such as farnesoid X receptor (FXR), vitamin D receptor (VDR) and Takeda G protein-coupled receptor 5 (TGR5) help to explain. Recent regulatory milestones include the FDA-approval of chenodeoxycholic acid (CDCA) in the treatment of cerebrotendinous xanthomatosis (CTX) and ongoing clinical trials such as that of norucholic acid (NCA) in the treatment of primary sclerosing cholangitis (PSC). Expanding research is redefining the BA therapeutic landscape, with applications spanning cholestatic, metabolic, and neurodegenerative diseases. This review will explore established and emerging BA-based monotherapies, combination regimens, and novel BA-driven drug delivery systems.<\/jats:p>","DOI":"10.3389\/fphar.2025.1732854","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:42Z","timestamp":1768196382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Bile acids as therapeutic agents"],"prefix":"10.3389","volume":"16","author":[{"given":"Brandon","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Villalba-Davila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wikrom","family":"Karnsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e70265","DOI":"10.1002\/jgh3.70265","article-title":"The efficacy and safety of seladelpar for primary biliary cholangitis: a systematic review and meta\u2010analysis","volume":"9","author":"Abuelazm","year":"2025","journal-title":"JGH Open An Open Access J. Gastroenterology Hepatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3109\/10717544.2014.976892","article-title":"Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide\/protein-based therapeutics or vaccines","volume":"23","author":"Aburahma","year":"2016","journal-title":"Drug Deliv."},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1194\/jlr.M400294-JLR200","article-title":"Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative","volume":"46","author":"Adachi","year":"2005","journal-title":"J. Lipid Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/toxsci\/kfn268","article-title":"Bile acid sulfation: a pathway of bile acid elimination and detoxification","volume":"108","author":"Alnouti","year":"2009","journal-title":"Toxicol. Sci. An Official J. Soc. Toxicol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","article-title":"Bile acids: regulation of apoptosis by ursodeoxycholic acid","volume":"50","author":"Amaral","year":"2009","journal-title":"J. Lipid Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fphar.2019.00977","article-title":"Endoplasmic reticulum stress activates unfolded protein response signaling and mediates inflammation, obesity, and cardiac dysfunction: therapeutic and molecular approach","volume":"10","author":"Amen","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cld.2022.03.001","article-title":"Biliary atresia in children: update on disease mechanism, therapies, and patient outcomes","volume":"26","author":"Antala","year":"2022","journal-title":"Clin. Liver Disease"},{"key":"B9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ijbiomac.2020.06.078","article-title":"Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: towards therapeutic implications in neurodegenerative diseases","volume":"161","author":"Anwar","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"120861","DOI":"10.1016\/j.lfs.2022.120861","article-title":"Alzheimer\u2019s disease failed clinical trials","volume":"306","author":"Asher","year":"2022","journal-title":"Life Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","article-title":"Recent advances in the management of primary sclerosing cholangitis","volume":"21","author":"Assis","year":"2023","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cld.2022.03.002","article-title":"Alagille syndrome: current understanding of pathogenesis, and challenges in diagnosis and management","volume":"26","author":"Ayoub","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s12072-023-10578-x","article-title":"Management of adults with alagille syndrome","volume":"17","author":"Ayoub","year":"2023","journal-title":"Hepatol. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.3390\/biomedicines12122910","article-title":"Bile acids in inflammatory bowel disease: from pathophysiology to treatment","volume":"12","author":"Bai","year":"2024","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clinre.2018.07.010","article-title":"Systematic review of progressive familial intrahepatic cholestasis","volume":"43","author":"Baker","year":"2019","journal-title":"Clin. Res. Hepatology Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1136\/gutjnl-2023-330856","article-title":"Protective function of sclerosing cholangitis on IBD","volume":"73","author":"Bedke","year":"2024","journal-title":"Gut"},{"key":"B18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/hep.1840160315","article-title":"Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial","volume":"16","author":"Beuers","year":"1992","journal-title":"Hepatol. Baltim. Md"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jhep.2025.06.010","article-title":"History and prospects of bile acid therapies","volume":"83","author":"Beuers","year":"2025","journal-title":"J. Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1264997","DOI":"10.3389\/fphar.2023.1264997","article-title":"Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patients","volume":"14","author":"Bouwhuis","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatol. Baltim. Md"},{"key":"B24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41586-020-2288-7","article-title":"C9orf72 suppresses systemic and neural inflammation induced by gut bacteria","volume":"582","author":"Burberry","year":"2020","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/164_2019_241","article-title":"UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications","volume":"256","author":"Cabrera","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41574-024-01067-8","article-title":"Bile acid metabolism in type 2 diabetes mellitus","volume":"21","author":"Cadena Sandoval","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"102759","DOI":"10.1016\/j.ebiom.2020.102759","article-title":"Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes","volume":"55","author":"Calderon","year":"2020","journal-title":"EBioMedicine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MOG.0000000000000807","article-title":"The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment","volume":"38","author":"Cariello","year":"2022","journal-title":"Curr. Opin. Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/ecco-jcc\/jjae082","article-title":"Epidemiology of inflammatory bowel disease across the ages in the era of advanced therapies","volume":"18","author":"Caron","year":"2024","journal-title":"J. Crohn\u2019s and Colitis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7342","DOI":"10.1038\/sj.onc.1204926","article-title":"Transcriptional regulation of bcl-2 by nuclear factor \u03baB and its significance in prostate cancer","volume":"20","author":"Catz","year":"2001","journal-title":"Oncogene"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/tomography10010005","article-title":"Primary sclerosing cholangitis: diagnostic criteria","volume":"10","author":"Cazzagon","year":"2024","journal-title":"Tomography"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2192155","DOI":"10.1080\/19490976.2023.2192155","article-title":"Glycoursodeoxycholic acid regulates bile acids level and alters gut microbiota and glycolipid metabolism to attenuate diabetes","volume":"15","author":"Chen","year":"2023","journal-title":"Gut Microbes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0314","DOI":"10.1097\/HC9.0000000000000314","article-title":"Diagnosis and management of alagille and progressive familial intrahepatic cholestasis","volume":"7","author":"Cheng","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1194\/jlr.M044420","article-title":"Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-Deficient mice","volume":"55","author":"Cheng","year":"2014","journal-title":"J. Lipid Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","article-title":"Bile acids: regulation of synthesis: thematic review series: bile acids","volume":"50","author":"Chiang","year":"2009","journal-title":"J. Lipid Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cphy.c120023","article-title":"Bile acid metabolism and signaling","volume":"3","author":"Chiang","year":"2013","journal-title":"Compr. Physiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"G554","DOI":"10.1152\/ajpgi.00223.2019","article-title":"Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy","volume":"318","author":"Chiang","year":"2020","journal-title":"Am. J. Physiology. Gastrointest. Liver Physiology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"150950","DOI":"10.1016\/j.sempedsurg.2020.150950","article-title":"Biliary atresia: east versus west","volume":"29","author":"Chung","year":"2020","journal-title":"Seminars Pediatr. Surg."},{"key":"B39","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","article-title":"Bile acids and the gut microbiota: metabolic interactions and impacts on disease","volume":"21","author":"Collins","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2125739","DOI":"10.1080\/19490976.2022.2125739","article-title":"Regulation of microglial physiology by the microbiota","volume":"14","author":"Cook","year":"2022","journal-title":"Gut Microbes"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1093\/ibd\/izac015.072","article-title":"Incidence and prevalence of primary sclerosing cholangitis: a meta-analysis of population-based studies","volume":"28","author":"Cooper","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e1905","DOI":"10.14309\/01.ajg.0000868364.31120.0e","article-title":"S2931 benign recurrent intrahepatic cholestasis (BRIC) managed with plasmapheresis","volume":"117","author":"Daniel","year":"2022","journal-title":"Official Journal Am. Coll. Gastroenterology | ACG"},{"key":"B43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MOL.0000000000000740","article-title":"Update on cerebrotendinous xanthomatosis","volume":"32","author":"DeBarber","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3390\/ijms22041780","article-title":"Physiology and physical chemistry of bile acids","volume":"22","author":"di Gregorio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/hep.30937","article-title":"Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice","volume":"71","author":"Dong","year":"2020","journal-title":"Hepatology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/MCO.0000000000001128","article-title":"Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease","volume":"28","author":"Duarte","year":"2025","journal-title":"Curr. Opin. Clin. Nutr. Metabolic Care"},{"key":"B47","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jacl.2023.07.002","article-title":"Treatment of cerebrotendinous xanthomatosis in pregnancy: patient and physician perspectives","volume":"17","author":"Duell","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/db11-0815","article-title":"Bile acids acutely stimulate insulin secretion of mouse \u03b2-cells via farnesoid X receptor activation and K(ATP) channel inhibition","volume":"61","author":"D\u00fcfer","year":"2012","journal-title":"Diabetes"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerozing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.2147\/IJN.S319255","article-title":"Liver targeting of daclatasvir via tailoring sterically stabilized bilosomes: fabrication, comparative in Vitro\/In Vivo appraisal and biodistribution studies","volume":"16","author":"El-Nabarawi","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2580910","DOI":"10.1080\/23995270.2025.2580910","article-title":"Elafibranor in the treatment of primary biliary cholangitis","volume":"5","author":"Ergenc","year":"2025","journal-title":"Future Rare Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17425247.2016.1178233","article-title":"Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents","volume":"13","author":"Faustino","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"B53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.livres.2021.07.002","article-title":"Bile acid receptors and signaling crosstalk in the liver, gut and brain","volume":"5","author":"Ferrell","year":"2021","journal-title":"Liver Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J. Hepatology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/164_2019_226","article-title":"Chenodeoxycholic acid: an update on its therapeutic applications","volume":"256","author":"Fiorucci","year":"","journal-title":"Handb. Exp. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"","journal-title":"Handb. Exp. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Investigational Drugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.3390\/cells13181580","article-title":"Current landscape and evolving therapies for primary biliary cholangitis","volume":"13","author":"Fiorucci","year":"2024","journal-title":"Cells"},{"key":"B59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1007813","DOI":"10.3389\/fped.2022.1007813","article-title":"Current and emerging adjuvant therapies in biliary atresia","volume":"10","author":"Fligor","year":"2022","journal-title":"Front. Pediatr."},{"key":"B61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1161\/CIRCRESAHA.117.311401","article-title":"Reactive oxygen species in metabolic and inflammatory signaling","volume":"122","author":"Forrester","year":"2018","journal-title":"Circulation Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J. Hepatology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","article-title":"Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets","volume":"8","author":"Gao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e335","DOI":"10.1097\/PG9.0000000000000335","article-title":"Resolution of pruritus in a child with alagille syndrome treated with maralixibat for seven years: durable response and discontinuation of other medications","volume":"4","author":"Garcia","year":"2023","journal-title":"JPGN Reports"},{"key":"B65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/metabo8040071","article-title":"Metabolomic profiling of bile acids in an experimental model of prodromal parkinson\u2019s disease","volume":"8","author":"Graham","year":"2018","journal-title":"Metabolites"},{"key":"B66","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1038\/s41467-023-38840-8","article-title":"Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis","volume":"14","author":"Gui","year":"2023","journal-title":"Nat. Commun."},{"key":"B67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/HMER.S137209","article-title":"Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment","volume":"10","author":"Gunaydin","year":"2018","journal-title":"Hepatic Med. Evid. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphys.2016.00646","article-title":"TGR5, not only a metabolic regulator","volume":"7","author":"Guo","year":"2016","journal-title":"Front. Physiology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/dmd.108.025155","article-title":"Mechanism of vitamin D receptor inhibition of cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes","volume":"37","author":"Han","year":"2009","journal-title":"Drug Metabolism Dispos. Biol. Fate Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jdiacomp.2017.01.011","article-title":"Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials","volume":"31","author":"Hansen","year":"2017","journal-title":"J. Diabetes Its Complicat."},{"key":"B71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/S0140-6736(09)60946-6","article-title":"Biliary atresia","volume":"374","author":"Hartley","year":"2009","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","article-title":"Cholestatic liver disease: current treatment strategies and new therapeutic agents","volume":"81","author":"Hasegawa","year":"2021","journal-title":"Drugs"},{"key":"B75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cld.2022.03.003","article-title":"Overview of progressive familial intrahepatic cholestasis","volume":"26","author":"Hassan","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet London, Engl."},{"key":"B77","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11894-023-00891-8","article-title":"Treatment of cholestasis in infants and young children","volume":"25","author":"Heinz","year":"2023","journal-title":"Curr. Gastroenterol. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0022-2275(20)38331-0","article-title":"Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions","volume":"30","author":"Heuman","year":"1989","journal-title":"J. Lipid Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J. Hepatology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J. Hepatology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B82","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/dom.12636","article-title":"Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?","volume":"18","author":"Hodge","year":"2016","journal-title":"Diabetes, Obes. and Metabolism"},{"key":"B83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1152\/physiologyonline.1999.14.1.24","article-title":"Bile acids: the good, the bad, and the ugly","volume":"14","author":"Hofmann","year":"1999","journal-title":"Physiology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00018-008-7568-6","article-title":"Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics","volume":"65","author":"Hofmann","year":"2008","journal-title":"Cell. Molecular Life Sciences CMLS"},{"key":"B85","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cld.2023.06.006","article-title":"Primary biliary cholangitis: pathophysiology","volume":"28","author":"Houri","year":"2024","journal-title":"Clin. Liver Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.emboj.7601049","article-title":"Endocrine functions of bile acids","volume":"25","author":"Houten","year":"2006","journal-title":"EMBO J."},{"key":"B87","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14218\/JCTH.2024.00123","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbi.2021.09.021","article-title":"From dried bear bile to molecular investigation: a systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders","volume":"99","author":"Huang","year":"2022","journal-title":"Brain, Behav. Immun."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s11739-025-03895-6","article-title":"Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030","volume":"20","author":"Huang","year":"2025","journal-title":"Intern. Emerg. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"108311","DOI":"10.1016\/j.pharmthera.2022.108311","article-title":"Bile acids and neurological disease","volume":"240","author":"Hurley","year":"2022","journal-title":"Pharmacol. and Ther."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int."},{"key":"B92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40673-021-00128-2","article-title":"Cerebrotendinous xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid","volume":"8","author":"Islam","year":"2021","journal-title":"Cerebellum and Ataxias"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet London, Engl."},{"key":"B94","doi-asserted-by":"publisher","first-page":"eade6924","DOI":"10.1126\/sciimmunol.ade6924","article-title":"Sulfated bile acid is a host-derived ligand for MAIT cells","volume":"9","author":"Ito","year":"2024","journal-title":"Sci. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e71549","DOI":"10.1002\/hsr2.71549","article-title":"FDA approves first targeted treatment for cerebrotendinous xanthomatosis: a perspective on a landmark in rare lipid storage disease therapy","volume":"8","author":"Jalal","year":"2025","journal-title":"Health Sci. Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e2462185","DOI":"10.1001\/jamanetworkopen.2024.62185","article-title":"Berberine ursodeoxycholate for the treatment of type 2 diabetes: a randomized clinical trial","volume":"8","author":"Ji","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B97","doi-asserted-by":"publisher","first-page":"774884","DOI":"10.3389\/fphar.2021.774884","article-title":"Comparative evidence for intrahepatic cholestasis of pregnancy treatment with traditional Chinese medicine therapy: a network meta-analysis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"116462","DOI":"10.1016\/j.ejmech.2024.116462","article-title":"Update on the development of TGR5 agonists for human diseases","volume":"271","author":"Jin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B99","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1080\/10717544.2020.1787557","article-title":"Molecular docking and statistical optimization of taurocholate-stabilized galactose anchored bilosomes for the enhancement of sofosbuvir absorption and hepatic relative targeting efficiency","volume":"27","author":"Joseph Naguib","year":"2020","journal-title":"Drug Deliv."},{"key":"B100","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41531-023-00531-y","article-title":"Targeted metabolomic analysis in Parkinson\u2019s disease brain frontal cortex and putamen with relation to cognitive impairment","volume":"9","author":"Kaleck\u00fd","year":"2023","journal-title":"Npj Parkinson\u2019s Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/hep4.1468","article-title":"Outcomes of childhood cholestasis in alagille syndrome: results of a multicenter observational study","volume":"4","author":"Kamath","year":"2020","journal-title":"Hepatol. Commun."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis \u2013 a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3803\/EnM.2021.1349","article-title":"Interplay of vitamin D and CYP3A4 polymorphisms in endocrine disorders and cancer","volume":"37","author":"Kasarla","year":"2022","journal-title":"Endocrinol. Metabolism"},{"key":"B104","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0b013e3181df5fd8","article-title":"Effect of Kasai procedure on hepatic outcome in alagille syndrome","volume":"51","author":"Kaye","year":"2010","journal-title":"J. Pediatr. Gastroenterology Nutr."},{"key":"B105","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"B106","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3390\/ijms18020289","article-title":"Decreased expression of vitamin D receptor affects an immune response in primary biliary cholangitis via the VDR-miRNA155-SOCS1 pathway","volume":"18","author":"Kempinska-Podhorodecka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40035-022-00307-z","article-title":"Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases","volume":"11","author":"Khalaf","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"B108","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes \u2013 global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"B109","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41531-021-00245-z","article-title":"Cholecystectomy and subsequent risk of Parkinson\u2019s disease: a nationwide retrospective cohort study","volume":"7","author":"Kim","year":"2021","journal-title":"Npj Parkinson\u2019s Dis."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e001001","DOI":"10.1136\/bmjgast-2022-001001","article-title":"Feasibility, safety and tolerability of the CREB-Binding protein\/\u03b2-catenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study","volume":"9","author":"Kimura","year":"2022","journal-title":"BMJ Open Gastroenterology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1002\/hep4.2043","article-title":"Inhibition of CBP\/\u03b2-catenin signaling ameliorated fibrosis in cholestatic liver disease","volume":"6","author":"Kimura","year":"2022","journal-title":"Hepatol. Commun."},{"key":"B112","doi-asserted-by":"publisher","first-page":"101449","DOI":"10.1016\/j.gim.2025.101449","article-title":"Efficacy, safety, and tolerability of chenodeoxycholic acid (CDCA) in adult patients with cerebrotendinous xanthomatosis (RESTORE): a randomized withdrawal, double-blind, placebo-controlled, crossover phase-3 study","volume":"27","author":"Kisanuki","year":"2025","journal-title":"Genet. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1055\/s-0041-1730951","article-title":"Alagille syndrome: a focused review on clinical features, genetics, and treatment","volume":"41","author":"Kohut","year":"2021","journal-title":"Seminars Liver Dis."},{"key":"B114","doi-asserted-by":"publisher","first-page":"e4949","DOI":"10.1097\/MD.0000000000004949","article-title":"Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy","volume":"95","author":"Kong","year":"2016","journal-title":"Medicine"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jpedsurg.2007.11.043","article-title":"Review of historical cohort: ursodeoxycholic acid in extrahepatic biliary atresia","volume":"43","author":"Kotb","year":"2008","journal-title":"J. Pediatr. Surg."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1053\/j.gastro.2024.06.014","article-title":"AGA clinical practice update on pregnancy-related gastrointestinal and liver disease: expert review","volume":"167","author":"Kothari","year":"2024","journal-title":"Gastroenterology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B119","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","article-title":"Pathogenesis and treatment of pruritus in cholestasis","volume":"68","author":"Kremer","year":"2008","journal-title":"Drugs"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab."},{"key":"B121","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.clinre.2012.06.006","article-title":"The bile salt export pump (BSEP) in health and disease","volume":"36","author":"Kubitz","year":"2012","journal-title":"Clin. Res. Hepatology Gastroenterology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molmet.2018.03.007","article-title":"Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas","volume":"11","author":"Kuhre","year":"2018","journal-title":"Mol. Metab."},{"key":"B123","doi-asserted-by":"publisher","first-page":"4187796","DOI":"10.1155\/2024\/4187796","article-title":"Beneficial effects of ursodeoxycholic acid on metabolic parameters and oxidative stress in patients with type 2 diabetes mellitus: a randomized double-blind, placebo-controlled clinical study","volume":"2024","author":"Laki\u0107","year":"2024","journal-title":"J. Diabetes Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bbrc.2010.06.022","article-title":"Tauroursodeoxycholate (TUDCA), chemical chaperone, enhances function of islets by reducing ER stress","volume":"397","author":"Lee","year":"2010","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"B2","DOI":"10.1016\/j.ajog.2020.11.002","article-title":"Society for maternal-fetal medicine consult series #53: intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011","volume":"224","author":"Lee","year":"2021","journal-title":"Am. J. Obstetrics and Gynecol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/ecco-jcc\/jjae096","article-title":"Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile","volume":"18","author":"Leibovitzh","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"B127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3748\/wjg.v29.i2.357","article-title":"Secondary bile acids and the biliary epithelia: the good and the bad","volume":"29","author":"Lenci","year":"2023","journal-title":"World J. Gastroenterology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/HEP.0000000000001166","article-title":"Primary biliary cholangitis: personalizing second-line therapies","volume":"82","author":"Levy","year":"2025","journal-title":"Hepatol. Baltim. Md"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin. Gastroenterology Hepatology Official Clin. Pract. J. Am. Gastroenterological Assoc."},{"key":"B130","doi-asserted-by":"publisher","first-page":"e0677","DOI":"10.1097\/HC9.0000000000000677","article-title":"A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers","volume":"9","author":"Levy","year":"","journal-title":"Hepatol. Commun."},{"key":"B131","doi-asserted-by":"publisher","first-page":"S0168","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","volume":"84","author":"Levy","year":"","journal-title":"J. Hepatology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"B133","first-page":"263","article-title":"Bile acid metabolism and signaling in cholestasis, inflammation, and cancer","volume-title":"Advances in pharmacology","author":"Li","year":"2015"},{"key":"B134","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/pr.113.008201","article-title":"Bile acid signaling in metabolic disease and drug therapy","volume":"66","author":"Li","year":"2014","journal-title":"Pharmacol. Rev."},{"key":"B135","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1074\/jbc.M111.305789","article-title":"Glucose and insulin induction of bile acid synthesis: mechanisms and implication in diabetes and obesity","volume":"287","author":"Li","year":"2012","journal-title":"J. Biol. Chem."},{"key":"B136","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/metabo11010029","article-title":"Gut microbiota dysbiosis is associated with elevated bile acids in parkinson\u2019s disease","volume":"11","author":"Li","year":"2021","journal-title":"Metabolites"},{"key":"B137","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474124.2022.2083605","article-title":"Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"16","author":"Lin","year":"2022","journal-title":"Expert Rev. Gastroenterology and Hepatology"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1016\/j.cell.2025.05.010","article-title":"A microbial amino-acid-conjugated bile acid, tryptophan-cholic acid, improves glucose homeostasis via the orphan receptor MRGPRE","author":"Lin","year":"2025","journal-title":"Cell"},{"key":"B139","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in oxidative stress","volume":"7","author":"Lingappan","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/toxsci\/kfu151","article-title":"Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures","volume":"141","author":"Liu","year":"2014","journal-title":"Toxicol. Sci. An Official J. Soc. Toxicol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1097\/DSS.0000000000003159","article-title":"Alternative cosmetic and medical applications of injectable deoxycholic acid: a systematic review","volume":"47","author":"Liu","year":"2021","journal-title":"Dermatol. Surg."},{"key":"B143","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"B144","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00261-022-03551-z","article-title":"Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis","volume":"48","author":"Ludwig","year":"2023","journal-title":"Abdom. Radiol. (New York)"},{"key":"B145","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jalz.2018.07.217","article-title":"Altered bile acid profile associates with cognitive impairment in alzheimer\u2019s disease \u2013 an emerging role for gut microbiome","volume":"15","author":"MahmoudianDehkordi","year":"2019","journal-title":"Alzheimer\u2019s and Dementia The Journal Alzheimer\u2019s Assoc."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1126\/science.1070477","article-title":"Vitamin D receptor as an intestinal bile acid sensor","volume":"296","author":"Makishima","year":"2002","journal-title":"Science"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00415-019-09377-y","article-title":"Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults","volume":"266","author":"Mandia","year":"2019","journal-title":"J. Neurology"},{"key":"B148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jpha.2023.06.007","article-title":"Protective effects of dioscin against Parkinson\u2019s disease via regulating bile acid metabolism through remodeling gut microbiome\/GLP-1 signaling","volume":"13","author":"Mao","year":"2023","journal-title":"J. Pharm. Analysis"},{"key":"B150","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cbi.2015.08.016","article-title":"Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: promising diagnostic biomarkers for cholestasis","volume":"255","author":"Masubuchi","year":"2016","journal-title":"Chemico-Biological Interact."},{"key":"B151","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/03639045.2017.1402922","article-title":"Exploiting bilosomes for delivering bioactive polysaccharide isolated from Enteromorpha intestinalis for hacking hepatocellular carcinoma","volume":"44","author":"Matloub","year":"2018","journal-title":"Drug Dev. Industrial Pharm."},{"key":"B152","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.tcb.2018.02.003","article-title":"Apoptotic caspases: multiple or mistaken identities?","volume":"28","author":"McArthur","year":"2018","journal-title":"Trends Cell Biol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.jhepr.2023.100949","article-title":"Opinion paper on the diagnosis and treatment of progressive familial intrahepatic cholestasis","volume":"6","author":"McKiernan","year":"2023","journal-title":"JHEP Rep."},{"key":"B154","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that May contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B155","doi-asserted-by":"publisher","first-page":"e44116","DOI":"10.7554\/eLife.44116","article-title":"Identification of a bilirubin receptor that May mediate a component of cholestatic itch","volume":"8","author":"Meixiong","year":"2025","journal-title":"eLife"},{"key":"B156","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet. Gastroenterology and Hepatology"},{"key":"B157","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-022-02177-0","article-title":"Impact of progressive familial intrahepatic cholestasis on caregivers: caregiver-reported outcomes from the multinational PICTURE study","volume":"17","author":"Mighiu","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"B158","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cld.2018.06.001","article-title":"Alagille syndrome","volume":"22","author":"Mitchell","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/molecules30051181","article-title":"The pharmaceutical and pharmacological potential applications of bilosomes as nanocarriers for drug delivery","volume":"30","author":"Mitrovi\u0107","year":"2025","journal-title":"Molecules"},{"key":"B160","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"B161","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/JAD-210608","article-title":"Bile acids as key modulators of the brain-gut-microbiota axis in alzheimer\u2019s disease","volume":"84","author":"Mulak","year":"2021","journal-title":"J. Alzheimer\u2019s Disease JAD"},{"key":"B163","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes and Endocrinol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1208\/s12249-023-02696-4","article-title":"Unlocking the potential of bilosomes and modified bilosomes: a comprehensive journey into advanced drug delivery trends","volume":"24","author":"Nayak","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"B165","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet London, Engl."},{"key":"B166","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B167","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jhep.2020.03.024","article-title":"Volixibat in adults with non-alcoholic steatohepatitis: 24-Week interim analysis from a randomized, phase II study","volume":"73","author":"Newsome","year":"2020","journal-title":"J. Hepatology"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1049850","DOI":"10.3389\/fneur.2022.1049850","article-title":"Cerebrotendinous xanthomatosis: a practice review of pathophysiology, diagnosis, and treatment","volume":"13","author":"N\u00f3brega","year":"2022","journal-title":"Front. Neurology"},{"key":"B169","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"B170","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","article-title":"Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis","volume":"6","author":"Ovadia","year":"2021","journal-title":"Lancet. Gastroenterology and Hepatology"},{"key":"B171","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet. Gastroenterology and Hepatology"},{"key":"B172","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/metabo7020028","article-title":"Metabolomic profiling of bile acids in clinical and experimental samples of alzheimer\u2019s disease","volume":"7","author":"Pan","year":"2017","journal-title":"Metabolites"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2356284","DOI":"10.1080\/19490976.2024.2356284","article-title":"Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis","volume":"16","author":"Pan","year":"2024","journal-title":"Gut Microbes"},{"key":"B174","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1152\/ajpgi.00028.2017","article-title":"Pregnancy and bile acid disorders","volume":"313","author":"Pataia","year":"2017","journal-title":"Am. J. Physiology. Gastrointest. Liver Physiology"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jaad.2019.04.035","article-title":"Cholestatic pruritus: emerging mechanisms and therapeutics","volume":"81","author":"Patel","year":"2019","journal-title":"J. Am. Acad. Dermatology"},{"key":"B176","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatol. Baltim. Md"},{"key":"B177","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatol. Baltim. Md"},{"key":"B178","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bcp.2009.08.017","article-title":"Intestinal cell-specific vitamin D receptor (VDR)-Mediated transcriptional regulation of CYP3A4 gene","volume":"79","author":"Pavek","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/mds.29450","article-title":"A double-blind, randomized, placebo-controlled trial of ursodeoxycholic acid (UDCA) in parkinson\u2019s disease","volume":"38","author":"Payne","year":"2023","journal-title":"Mov. Disord."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J. Gastroenterology. WJG"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2010.12.004","article-title":"The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation","volume":"54","author":"Pols","year":"2011","journal-title":"J. Hepatology"},{"key":"B182","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"key":"B183","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1021\/acsomega.2c05976","article-title":"Surface modification of lipid-based nanocarriers: a potential approach to enhance targeted drug delivery","volume":"8","author":"Priya","year":"2023","journal-title":"ACS Omega"},{"key":"B184","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.3748\/wjg.v12.i22.3487","article-title":"Ursodeoxycholic acid treatment of vanishing bile duct syndromes","volume":"12","author":"Pusl","year":"2006","journal-title":"World J. Gastroenterology. WJG"},{"key":"B185","doi-asserted-by":"publisher","first-page":"e12005","DOI":"10.1097\/MD.0000000000012005","article-title":"Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of Kasai procedure: a systematic review and meta-analysis","volume":"97","author":"Qiu","year":"2018","journal-title":"Medicine"},{"key":"B186","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.dld.2014.01.159","article-title":"Bile acids permeabilize the blood brain barrier after bile duct ligation","volume":"46","author":"Quinn","year":"2014","journal-title":"Dig. Liver Disease. Official Journal Italian Soc. Gastroenterology Italian Assoc. Study Liver"},{"key":"B187","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41586-020-2047-9","article-title":"Global chemical effects of the microbiome include new bile-acid conjugations","volume":"579","author":"Quinn","year":"2020","journal-title":"Nature"},{"key":"B188","doi-asserted-by":"publisher","first-page":"110364","DOI":"10.1016\/j.exer.2025.110364","article-title":"Bilosomes as a novel ocular drug delivery system: assessing the material attributes, process parameters, and quality attributes","volume":"255","author":"Rajbhar","year":"2025","journal-title":"Exp. Eye Res."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Medicine"},{"key":"B190","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatology"},{"key":"B191","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/HEP.0000000000000980","article-title":"Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: results of multimodality assessment using both conventional and digital pathology","volume":"81","author":"Ratziu","year":"2025","journal-title":"Hepatol. Baltim. Md"},{"key":"B192","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/gutjnl-2015-309458","article-title":"TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro","volume":"65","author":"Reich","year":"2016","journal-title":"Gut"},{"key":"B193","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatol. Baltim. Md"},{"key":"B194","doi-asserted-by":"publisher","first-page":"e1901","DOI":"10.1002\/hsr2.1901","article-title":"Global incidence of intrahepatic cholestasis of pregnancy: a protocol for systematic review and meta-analysis","volume":"7","author":"Sadeghi","year":"2024","journal-title":"Health Sci. Rep."},{"key":"B195","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.cgh.2014.04.038","article-title":"The fatty acid-bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease","volume":"12","author":"Safadi","year":"2014","journal-title":"Clin. Gastroenterology Hepatology Official Clin. Pract. J. Am. Gastroenterological Assoc."},{"key":"B196","doi-asserted-by":"publisher","first-page":"e0218459","DOI":"10.1371\/journal.pone.0218459","article-title":"Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-\/-.Leiden mice","volume":"14","author":"Salic","year":"2019","journal-title":"PloS One"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","article-title":"Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson\u2019s disease","volume":"167","author":"Sampson","year":"2016","journal-title":"Cell"},{"key":"B198","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"B199","doi-asserted-by":"publisher","first-page":"170","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"B200","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fphar.2018.00939","article-title":"Bile acid synthesis: from nature to the chemical modification and synthesis and their applications as drugs and nutrients","volume":"9","author":"\u0160arenac","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1021\/acs.jmedchem.0c01420","article-title":"Lithocholic acid derivatives as potent vitamin D receptor agonists","volume":"64","author":"Sasaki","year":"2021","journal-title":"J. Med. Chem."},{"key":"B202","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ddmod.2004.10.004","article-title":"Pathways and defects of bile acid synthesis: insights from in vitro and in vivo experimental models","volume":"1","author":"Schwarz","year":"2004","journal-title":"Drug Discov. Today Dis. Models"},{"key":"B203","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom10050789","article-title":"MARK4 inhibited by AChE inhibitors, donepezil and rivastigmine tartrate: insights into alzheimer\u2019s disease therapy","volume":"10","author":"Shamsi","year":"2020","journal-title":"Biomolecules"},{"key":"B204","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","article-title":"Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry","volume":"16","author":"Shao","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"B205","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/bmjdrc-2017-000469","article-title":"Ursodeoxycholic acid potentiates dipeptidyl peptidase-4 inhibitor sitagliptin by enhancing glucagon-like peptide-1 secretion in patients with type 2 diabetes and chronic liver disease: a pilot randomized controlled and add-on study","volume":"6","author":"Shima","year":"2018","journal-title":"BMJ Open Diabetes Research and Care"},{"key":"B206","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.drudis.2016.03.013","article-title":"Bilosomes in the context of oral immunization: development, challenges and opportunities","volume":"21","author":"Shukla","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B207","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/molecules27061983","article-title":"A recent ten-year perspective: bile acid metabolism and signaling","volume":"27","author":"Shulpekova","year":"2022","journal-title":"Molecules"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001539","article-title":"Bile acid signaling in MASLD: from pathogenesis to therapeutic applications","author":"Simbrunner","year":"2025","journal-title":"Hepatol. Baltim. Md"},{"key":"B209","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/GRF.0000000000000495","article-title":"Intrahepatic cholestasis of pregnancy","volume":"63","author":"Smith","year":"2020","journal-title":"Clin. Obstetrics Gynecol."},{"key":"B210","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1530\/EJE-14-0154","article-title":"Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion","volume":"171","author":"Sonne","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","article-title":"Liver disease associated with canalicular transport defects: current and future therapies","volume":"52","author":"Stapelbroek","year":"2010","journal-title":"J. Hepatology"},{"key":"B212","doi-asserted-by":"publisher","first-page":"e186420","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J. Clin. Investigation"},{"key":"B213","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.bbi.2020.10.014","article-title":"Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson\u2019s disease via gut microbiota-GLP-1 pathway","volume":"91","author":"Sun","year":"2021","journal-title":"Brain, Behav. Immun."},{"key":"B214","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41522-024-00610-9","article-title":"Unlocking gut-liver-brain axis communication metabolites: energy metabolism, immunity and barriers","volume":"10","author":"Sun","year":"2024","journal-title":"Npj Biofilms Microbiomes"},{"key":"B215","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-pathmechdis-031521-025623","article-title":"Pediatric cholestatic diseases: common and unique pathogenic mechanisms","volume":"19","author":"Sutton","year":"2024","journal-title":"Annu. Rev. Pathology"},{"key":"B216","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1074\/jbc.RA119.011913","article-title":"Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet\u2013fed mice","volume":"295","author":"Takahashi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"B217","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.jpha.2024.100979","article-title":"Targeting NTCP for liver disease treatment: a promising strategy","volume":"14","author":"Tan","year":"2024","journal-title":"J. Pharm. Analysis"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"B219","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41467-023-36981-4","article-title":"Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"B220","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s12072-023-10604-y","article-title":"Intrahepatic cholestasis of pregnancy: insights into pathogenesis and advances in omics studies","volume":"18","author":"Tang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B221","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic dysfunction-associated steatotic liver disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B222","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases","volume":"7","author":"Thomas","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"B223","doi-asserted-by":"publisher","first-page":"829525","DOI":"10.3389\/fimmu.2022.829525","article-title":"The emerging role of bile acids in the pathogenesis of inflammatory bowel disease","volume":"13","author":"Thomas","year":"2022","journal-title":"Front. Immunol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet. Gastroenterology and Hepatology"},{"key":"B225","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatol. Baltim. Md"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"B227","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/ejhg.2011.181","article-title":"Alagille syndrome: pathogenesis, diagnosis and management","volume":"20","author":"Turnpenny","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"B228","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s44321-023-00021-x","article-title":"FGF19 and its analog aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis","volume":"16","author":"Ursic-Bedoya","year":"2024","journal-title":"EMBO Molecular Medicine"},{"key":"B229","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3748\/wjg.v23.i5.763","article-title":"Current and future therapies for inherited cholestatic liver diseases","volume":"23","author":"van der Woerd","year":"2017","journal-title":"World J. Gastroenterology"},{"key":"B230","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J. Hepatology"},{"key":"B231","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.32761","article-title":"Natural history of liver disease in a large international cohort of children with alagille syndrome: results from the GALA study","volume":"77","author":"Vandriel","year":"2023","journal-title":"Hepatol. Baltim. Md"},{"key":"B232","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JAD-2010-100909","article-title":"Modulation of Amyloid-\u03b2 peptide-induced toxicity through inhibition of JNK nuclear localization and Caspase-2 activation","volume":"22","author":"Viana","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"B233","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.4254\/wjh.v13.i12.2024","article-title":"Newer variants of progressive familial intrahepatic cholestasis","volume":"13","author":"Vinayagamoorthy","year":"2021","journal-title":"World J. Hepatology"},{"key":"B234","doi-asserted-by":"publisher","first-page":"CD000493","DOI":"10.1002\/14651858.CD000493.pub3","article-title":"Pharmacological interventions for treating intrahepatic cholestasis of pregnancy","volume":"2020","author":"Walker","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B235","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1007\/s12035-023-03340-9","article-title":"Connecting the gut microbiota and neurodegenerative diseases: the role of bile acids","volume":"60","author":"Wang","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"20194","DOI":"10.1021\/acs.jafc.4c04630","article-title":"Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism","volume":"72","author":"Wang","year":"2024","journal-title":"J. Agric. Food Chem."},{"key":"B237","doi-asserted-by":"publisher","first-page":"G550","DOI":"10.1152\/ajpgi.00256.2016","article-title":"Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the Colon","volume":"312","author":"Ward","year":"2017","journal-title":"Am. J. Physiology. Gastrointest. Liver Physiology"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fphar.2020.01084","article-title":"Mechanism of hydrophobic bile acid-induced hepatocyte injury and drug discovery","volume":"11","author":"Wei","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/1061186X.2012.747528","article-title":"Characterization and optimization of bilosomes for oral vaccine delivery","volume":"21","author":"Wilkhu","year":"2013","journal-title":"J. Drug Target."},{"key":"B240","doi-asserted-by":"publisher","first-page":"e1236","DOI":"10.1542\/peds.2008-0986","article-title":"Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia","volume":"122","author":"Willot","year":"2008","journal-title":"Pediatrics"},{"key":"B241","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"B242","doi-asserted-by":"publisher","first-page":"167972","DOI":"10.1016\/j.bbadis.2025.167972","article-title":"The role of bile salts in itch receptor activation","volume":"1871","author":"Wolters","year":"2025","journal-title":"Biochimica Biophysica Acta. Mol. Basis Dis."},{"key":"B243","doi-asserted-by":"publisher","first-page":"117228","DOI":"10.1016\/j.biopha.2024.117228","article-title":"Molecular mechanism and therapeutic strategy of bile acids in Alzheimer\u2019s disease from the emerging perspective of the microbiota\u2013gut\u2013brain axis","volume":"178","author":"Wu","year":"","journal-title":"Biomed. and Pharmacother."},{"key":"B244","doi-asserted-by":"publisher","first-page":"106650","DOI":"10.1016\/j.biocel.2024.106650","article-title":"Microtubules and cardiovascular diseases: insights into pathology and therapeutic strategies","volume":"175","author":"Wu","year":"","journal-title":"Int. J. Biochem. and Cell Biol."},{"key":"B245","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13578-023-01053-z","article-title":"Roles of bile acids signaling in neuromodulation under physiological and pathological conditions","volume":"13","author":"Xing","year":"2023","journal-title":"Cell and Biosci."},{"key":"B246","doi-asserted-by":"publisher","first-page":"2168101","DOI":"10.1080\/19490976.2023.2168101","article-title":"Gut microbiota alteration after cholecystectomy contributes to post-cholecystectomy diarrhea via bile acids stimulating colonic serotonin","volume":"15","author":"Xu","year":"2023","journal-title":"Gut Microbes"},{"key":"B247","doi-asserted-by":"publisher","first-page":"16690","DOI":"10.18632\/aging.103992","article-title":"Metabolic alterations in plasma from patients with familial and idiopathic Parkinson\u2019s disease","volume":"12","author":"Yakhine-Diop","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B248","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbrc.2007.07.001","article-title":"Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes","volume":"361","author":"Yang","year":"2007","journal-title":"Biochem. Biophysical Res. Commun."},{"key":"B249","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1123967","DOI":"10.3389\/fnins.2023.1123967","article-title":"Liver\u2019s influence on the brain through the action of bile acids","volume":"17","author":"Yeo","year":"2023","journal-title":"Front. Neurosci."},{"key":"B251","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet London, Engl."},{"key":"B252","doi-asserted-by":"publisher","first-page":"e48431","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"eLife"},{"key":"B253","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.gim.2024.101086","article-title":"Chenodeoxycholic acid (CDCA) treatment during pregnancy in women with cerebrotendinous xanthomatosis (CTX): lessons learned from 19 pregnancies","volume":"26","author":"Zaccai","year":"2024","journal-title":"Genet. Med. Official J. Am. Coll. Med. Genet."},{"key":"B254","doi-asserted-by":"publisher","first-page":"119252","DOI":"10.1016\/j.lfs.2021.119252","article-title":"The bile acid TUDCA and neurodegenerative disorders: an overview","volume":"272","author":"Zangerolamo","year":"2021","journal-title":"Life Sci."},{"key":"B255","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.3390\/ijms26146547","article-title":"The critical role of the bile acid receptor TGR5 in energy homeostasis: insights into physiology and therapeutic potential","volume":"26","author":"Zangerolamo","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B256","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1111\/apt.12084","article-title":"Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease","volume":"36","author":"Zarrinpar","year":"2012","journal-title":"Alimentary Pharmacol. and Ther."},{"key":"B257","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41598-017-02825-7","article-title":"Release of cytochrome C from bax pores at the mitochondrial membrane","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"B258","doi-asserted-by":"publisher","first-page":"e00368","DOI":"10.1002\/prp2.368","article-title":"Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models","volume":"5","author":"Zhang","year":"2017","journal-title":"Pharmacol. Res. and Perspect."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1732854\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:39:44Z","timestamp":1768196384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1732854\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":258,"alternative-id":["10.3389\/fphar.2025.1732854"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1732854","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1732854"}}